Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Depreciation and Depletion (2016 - 2024)

CNBX Pharmaceuticals (CNBX) has disclosed Depreciation and Depletion for 13 consecutive years, with $32859.0 as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Depreciation and Depletion fell 18.65% year-over-year to $32859.0, compared with a TTM value of $32859.0 through Nov 2024, down 79.25%, and an annual FY2024 reading of $72320.0, down 55.37% over the prior year.
  • Depreciation and Depletion was $32859.0 for Q1 2024 at CNBX Pharmaceuticals, down from $39461.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $63230.0 in Q2 2020 and bottomed at $32859.0 in Q1 2024.
  • Average Depreciation and Depletion over 5 years is $48083.0, with a median of $48828.0 recorded in 2022.
  • The sharpest move saw Depreciation and Depletion surged 38.73% in 2020, then decreased 20.16% in 2023.
  • Year by year, Depreciation and Depletion stood at $57505.0 in 2020, then decreased by 9.88% to $51823.0 in 2021, then decreased by 16.67% to $43185.0 in 2022, then decreased by 8.62% to $39461.0 in 2023, then dropped by 16.73% to $32859.0 in 2024.
  • Business Quant data shows Depreciation and Depletion for CNBX at $32859.0 in Q1 2024, $39461.0 in Q4 2023, and $38492.0 in Q3 2023.